Major new trans Tasman healthcare fund:
This article was originally published in Clinica
Executive Summary
A new venture capital fund of NZ$150m (US$110m) is seeking to invest in companies from a broad range of life science sectors, including medical devices. BioPacificVentures (www.lifescienceventures.co.nz) is a collaboration of New Zealand venture capital firms AgResearch and Direct Capital, and one Swiss firm iventages venture capital. Its cornerstone international investor is Nestle, and Wrightson for New Zealand. "Monies are available immediately", Dr Andrew Kelly, of Direct Capital, told Clinica. "However, our expectation is that investing the money will take several years. We have advised our investors to expect six years of investment followed by six years as the companies grow and mature."
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.